(PCVX) Vaxcyte - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085

PCVX: Vaccines, Proteins, Antibiotics, Bacteria, Diseases, Prevention

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage biotechnology company, is at the forefront of developing innovative protein vaccines to combat bacterial infectious diseases. Their approach focuses on precision and efficiency, leveraging cutting-edge science to address significant public health challenges.

Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine, designed to offer broader protection against invasive pneumococcal disease compared to existing vaccines. This could potentially capture a substantial share of the multi-billion-dollar pneumococcal vaccine market.

Antibiotic resistance is a growing global concern, and Vaxcyte is tackling this head-on with VAX-31, aimed at emerging strains, and VAX-A1, targeting Group A Streptococcus, a major cause of infections. These efforts position the company to address unmet needs in infectious disease prevention.

Beyond respiratory infections, Vaxcyte is exploring other high-impact areas. VAX-PG targets periodontitis, a condition affecting millions, and VAX-GI aims to prevent Shigella, a significant cause of diarrhea globally. This diversified pipeline underscores the companys commitment to broad public health impact.

Since renaming from SutroVax in 2020, Vaxcyte has established itself in San Carlos, California. Their market cap of ~$1.1 billion reflects investor confidence in their pipeline and technology. With a price-to-book ratio of 3.25, they are well-positioned for future growth and partnerships in the biotech and pharmaceutical industries.

Additional Sources for PCVX Stock

PCVX Stock Overview

Market Cap in USD 9,576m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-06-12

PCVX Stock Ratings

Growth 5y 38.7%
Fundamental -54.6%
Dividend 0.0%
Rel. Strength -34.6
Analysts 4.82/5
Fair Price Momentum 30.23 USD
Fair Price DCF -

PCVX Dividends

No Dividends Paid

PCVX Growth Ratios

Growth Correlation 3m -75.2%
Growth Correlation 12m 40.9%
Growth Correlation 5y 76.9%
CAGR 5y 4.44%
CAGR/Max DD 5y 0.06
Sharpe Ratio 12m 0.20
Alpha -59.59
Beta 1.023
Volatility 49.88%
Current Volume 8890.5k
Average Volume 20d 984.9k
What is the price of PCVX stocks?
As of April 02, 2025, the stock is trading at USD 32.23 with a total of 8,890,452 shares traded.
Over the past week, the price has changed by -48.85%, over one month by -48.29%, over three months by -53.87% and over the past year by -43.41%.
Is Vaxcyte a good stock to buy?
No, based on ValueRay Fundamental Analyses, Vaxcyte (NASDAQ:PCVX) is currently (April 2025) a stock to sell. It has a ValueRay Fundamental Rating of -54.57 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PCVX as of April 2025 is 30.23. This means that PCVX is currently overvalued and has a potential downside of -6.21%.
Is PCVX a buy, sell or hold?
Vaxcyte has received a consensus analysts rating of 4.82. Therefor, it is recommend to buy PCVX.
  • Strong Buy: 9
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for PCVX stock price target?
According to ValueRays Forecast Model, PCVX Vaxcyte will be worth about 33.8 in April 2026. The stock is currently trading at 32.23. This means that the stock has a potential upside of +4.78%.
Issuer Forecast Upside
Wallstreet Target Price 150.2 366.1%
Analysts Target Price 149.9 365.1%
ValueRay Target Price 33.8 4.8%